[Hematopoietic stem cells and immune status of subjects with different hypoxic tolerance].

Intermittent hypoxia treatment (IHT) is gaining attention as a clinical modality due to its capacity to protect cells, tissues, organs, and the whole organism from more intense and/or sustained hypoxia, ischemia and other stresses, to enhance physical and mental capacity. Circulating hematopoietic stem and progenitor cells (HSPC) play an important role in immune response to hypoxia ensuring tissue reparation processes, formation of all types of blood cells etc. There exist considerable individual differences in the capability to mobilize HSPC.

[Clinico-immunological studies on the therapeutic efficacy of Immunal in acute bronchitis in children frequently and persistently ill].

Efficacy was studied of the use of the drug preparation "Immunal" (LEK, Slovenia [correction of Slovakia]) in a combined treatment of acute bronchitis in children in poor health. The main group of 39 children received conventional treatment supplemented with a course of the drug "Immunal", 10 drops on a three-times daily schedule over 30 days. The use of "Immunal" in a complex therapy of acute bronchitis in children made for a sooner disappearance of clinical manifestations of the illness, decline in ESR, rise in IgG.